Wojewódzki Szpital Zakaźny w Warszawie

Publikacje naukowe

Obecnie dostępne publikacje naukowe naszych pracowników:

15th European AIDS Conference

The 15th European AIDS Conference will be held in Barcelona, Spain from October 21 - 24, 2015

Genotype-specific predictors of early viral clearance following treatment with peginterferon alfa-2a (40KD) (PegIFNα-2a) plus ribavirin (RBV): multiple logistic regression analysis from the large multinational PROPHESYS cohorts.

Hanna Berak, Anna Kołakowska-Rządzka, Marek Wasilewski, Janusz J. Stańczak, Justyna Kowalska, Krzysztof Bardadin, Bożena Walewska-Zielecka, Andrzej Horban - “Randomized, open label trial comparing efficacy and safety of pegylated interferon alfa 2a vs alfa 2b treatment of patients with chronic hepatitis C infected with non 2/3 genotypes – Final analysis”.

Hanna Berak, Anna Kołakowska-Rządzka, Marek Wasilewski, Janusz Stańczak, Andrzej Horban - "Randomized, open label trial to compare efficiacy and safety of pegylated nterferon alfa da vs alfa 2b treatment of patients with chronic hepatitis c - 12  weeks virological response among patients with genotype non 2/3 analysis".

Hanna Berak, Anna Kołakowska-Rządzka, Marek Wasilewski, Janusz Stańczak, Katarzyna Szamotulska, Krzysztof Bardadin, , Andrzej Horban - "Comparison of efficacy of treatment with peginterferon alfa-2a plus ribavirin vs peginterferon alfa-2b plus ribavirin among patients chronically infected with non 2/3 HCV genotypes with low and high pretreatment viral load".

Anna Kołakowska-Rzadzka, Hanna Berak, Marek Wasilewski, Janusz Stańczak, Krzysztof Bardadin, Bożena Walewska- Zielecka, Andrzej Horban - "Relevance between fibrosis and response to treatment with peginterferon alfa 2a vs alfa 2b with ribavirin among chronic hepatitis c genotype 3 patients. Randomized open label study".

Justyna Dominika Kowalska, Pernille Ravn, Hanna Czeszko-Paprocka, Ewa Firląg-Burkacka, Andrzej Horban - "Single IFN-y assay testing is of limited use for health care workers occupational exposure screening in a high tuberculosis prevalence country."

R. B. Podlasin, A. Wiercińska-Drapalo, A Olczak, M. Beniowski, T. Smiatacz, E. Malolepsza, J. Juszczyk, M. Leszczyn-Pynka, T. Mach, M. Mian, B. Knysz, A. Horban - "Opportinistic Infrcions and Other AIDS-defining Illnesses in Poland in 2000-2002"

W. Halota, D. Delić, Z. Nesić, D. Prokopowicz, R. Flisiak, J. Kuydowicz, M. Jabłkowski, J. Cianciara, T. Mach, R. Modrzewska, M. Fabri, D. Tomić, A. Horban, W. Kryczka, J. Schneider, G. Pearce - "A novel PrimeBoost Immunotherapy induces high levels of HBeAg loss after 14 weeks in Patients with HBeAg + Chronic Hepatitis B: A Phase IIa Clinical Trial"

J. D. Kowalska, E. Firląg-Burkacka, M. Niezabitowska, E. Bąkowska, J. Gizińska, J. Higersbereger, A. Ignatowska, G. Karczewski, P. Pulik, P. Święcki, A. Horban - "Tolerability and adherence to post-exposure prophylaxis of HIV infection in different exposure groups"

M. Niezabitowska, E. Firląg-Burkacka, J. D. Kowalska, E. Bąkowska, J. Gizińska, J. Higersberger, A. Ignatowska, G. Karczewski, P. Pulik, P. Œwięcki, A. Horban - "Analysis of consultations and tests schedule for HIV infection after exposure to potentially infectious material (PIM) in different exposure groups"

H. Berak, A. Kołakowska-Rządzka, M. Wasilewski, J. Stańczak, A. Horban - "Randomized, open label trial to come efficacy and safety of pegylated Inrferon Alfa 2A v. Interferon Alfa 2b treatment of patient with chronic Hepatisis C - 12 weeks virological response among paties with with gentype non 2/3 analysis "

J. Stańczak, U. Komorowska, E Tobolewska, M. Majchrzak - "Współczesna diagnostyka zakażeń wirusem zapalenia wątroby typu C (HCV); Modern diagnostics of Hepatitis C Virus"

I. Szkop, H. Czeszko - Paprocka - "Walidacja metody pomiarowej"

S. Walmsley, A. Horban, R. Jain, C. Garris, T. Stark - "Fosamprenavir/ritonavir and Nelfinavir have Comparable Effects on Body Fat Changes in Antiretroviral-naive Patients: 48-Week Results from the SOLO Study"

AN. Phillips, B. Ledergerber, A. Horban, P. Reiss, A. Chiesi, O. Kirk, F. Mulcahy, M. Fisher, L. Machala, JD. Lundgren (for the EuroSIDA Study group) - " Rate of viral rebound in 539 patients with < 50 copies/mL on efavirenz-containing regimens, according to concomitant use of 3TC or ddI"

A. Mocroft, B. Ledergerber, JP. Viard, S. Staszewski, M. Murphy, A. Chiesi, A. Horban, AB. Hansen, AN. Phillips, JD. Lundgren (for the EuroSIDA study group) - " Time to Triple Drug Class Failure after Initiation of HAART"

A. Mocroft, B. Ledergerber, JP. Viard, S. Staszewski, M. Murphy, A. Chiesi, A. Horban, A-B. E. Hansen, AN. Phillips, JD. Lundgren (for the EuroSIDA study group) - "Time to triple drug class antiretroviral treatment failure after initiation of HAART: Results from the EuroSIDA study group"

S. Walmsley, A. Horban, R. Jain , C. Garris, T. Stark - " Fosamprenavir/ritonavir and Nelfinavir have Comparable Effects on Body Fat Changes in Antiretroviral-naive Patients: 48-Week Results from the SOLO Study"

H. Czeszko-Paprocka, C. Szczerbińska, M. Suwała, Z. Żuk, K. Roze - "Ocena analizatora chemii klinicznej Pentra 400 firmy Horiba ABX"

W. Banister, L. Ruiz, C. Loveday, S. Vella, K. Zilmer, D.Podlekareva, B. Knysz, A. Philips, J. Lundgren, A. Mocroft - "HIV1 Subtypes and Virological Response to HAART in Europe"

D.A.M.C. van de Vijver, A.M.J. Wensing, G. Angarano, B. Asjö, C. Balotta, E. Boeri, R. Camacho, M-L. Chaix, D. Costagliola, E.L.M. Op de Coul, A. de Luca, I. Maljkovic, C. de Mendoza, I. Derdelinckx, Z. Grossman, O. Hamouda, A. Hatzakis, I.M. Hoepelman, R. Hemmer, A. Horban, K. Korn, C. Kücherer, T. Leitner, C. Loveday, E. MacRae, L. Meyer, C. Nielsen, V. Ormaasen, L. Perrin, D. Paraskevis, E. Puchhammer-Stöckl, L. Ruiz, .M Salminen, J.C.C. Schmit, F. Schneider, R. Schuurman, V. Soriano, G. Stanczak, M. Stanojevic, A-M. Vandamme, K. Van Laethem, M. Violin, K. Wilbe, S. Yerly, M. Zazzi, C.A.B. Boucher (on behalf of the SPREAD Programme) - "Potential impact of differences in frequency of minor substitutions between HIV-1 subtypes on the genetic barrier for resistance to protease inhibitors"

RB Pollard, M Thompson, C Hicks, B Grinsztejn, A Horban, P Cernohous, J Omachi, M Norton, M King, S Brun - "Phase 3 comparison of lopinavir/ritonavir vs. investigator-selected protease inhibitors in single PI-experienced, NNRTI-naive patients: 48-week results of study M98-888"

H. Berak - "Efekty leczenia lamiwudyną przewlekłych wirusowych zapaleń wątroby typu B na podstawie materiału własnego"

Telefony

Centrala szpitala:
(22) 33 55 351 do 355
Poradnia chorób zakaźnych:
(22) 33 55 332 | (22) 33 55 235

Informacje bieżące

Urząd Marszałkowski 
Serwis Internetowy Urzędu Marszałkowskiego - organu założycielskiego szpitala
 
Główny Inspektor Sanitarny 
Serwis Głównego Inspektora Sanitarnego 
 
NFZ 
Serwis internetowy Narodowego Funduszu Zdrowia
 
Ministerstwo Zdrowia 
Serwis internetowy Ministerstwa Zdrowia RP